RUXREBO
Live / Allowed — Publication / registration review complete (as of 10 Sept 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 14 Jan 2026 filing date already counts against anyone who files later.
Record
- Serial number
- 99594277
- Mark type
- Stylized text
- Filed
- 14 Jan 2026
- Published for opposition
- 29 Sept 2026
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Anti-infectives; Vaccines
Owner
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 04 Sept 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Sept 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 03 Sept 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 03 Sept 2026 — TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
- 19 May 2026 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 19 May 2026 — LETTER OF SUSPENSION E-MAILED
- 19 May 2026 — SUSPENSION LETTER WRITTEN
- 12 May 2026 — ASSIGNED TO EXAMINER
- 14 Jan 2026 — APPLICATION FILING RECEIPT MAILED
- 14 Jan 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 14 Jan 2026 — NEW APPLICATION ENTERED